Core Viewpoint - The stock of Gilead Sciences-B (01672) has increased over 30% in the month, with a current price of HKD 18.24 and a trading volume of HKD 17.99 million, following the announcement of its first oral glucagon-like peptide-1 receptor agonist, ASC36, entering clinical development [1] Group 1 - The company announced on February 11 that it has selected ASC36 oral tablets for clinical development, with plans to submit an Investigational New Drug (IND) application to the FDA in the second quarter of 2026 for obesity treatment [1] - ASC36 is expected to have superior oral bioavailability and efficacy compared to a recently FDA-approved GLP-1R agonist, potentially allowing for lower dosing [1] - The weight loss effect per milligram of ASC36 peptide is anticipated to be more effective, which may lead to lower manufacturing costs due to scalability advantages [1] Group 2 - ASC36 is developed using the company's proprietary Artificial Intelligence-assisted Structure-Based Drug Discovery (AISBDD) technology [1] - The oral tablet formulation of ASC36 has been optimized using the company's proprietary POTENT technology for effective oral peptide delivery [1]
歌礼制药-B再涨超7% 预计将于第二季度向FDA递交ASC36口服片治疗肥胖症的IND